DecImmune Therapeutics, a US-based healthcare company, has raised $2.25m from a consortium including Astellas Venture Management, the corporate venturing division of Japan-based pharmaceutical company Astellas.
Broadview Ventures, the family office of the Leducq Family Trust and a new investor in DecImmune, and venture capital firm HealthCare Ventures joined Astellas in the round.
In September 2010, DecImmune raised $1m in its series B round from Astellas and HealthCare.
Janis Naeve, director of Amgen Ventures, the corporate venturing unit of US peer Amgen, was also named in the regulatory filing as a backer of DecImmune’s second round. Amgen is understood to have declined to be part of the latest round.
In September 2006, DecImmune raised $2.1m in its series A round, according to a regulatory filing seen by news provider PEWeek.